Headlines about Voyager Therapeutics (NASDAQ:VYGR) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.6878079038531 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Voyager Therapeutics (NASDAQ:VYGR) traded down $0.91 on Wednesday, reaching $17.47. 250,000 shares of the company were exchanged, compared to its average volume of 295,720. The firm has a market capitalization of $477.28 and a price-to-earnings ratio of -6.15. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.17). Voyager Therapeutics had a negative return on equity of 65.50% and a negative net margin of 1,195.63%. analysts forecast that Voyager Therapeutics will post -2.99 EPS for the current fiscal year.

VYGR has been the topic of several research analyst reports. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Raymond James Financial initiated coverage on shares of Voyager Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 target price on the stock. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Stifel Nicolaus reiterated a “buy” rating and issued a $31.00 target price (up previously from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Finally, Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They issued a “buy” rating and a $35.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. Voyager Therapeutics presently has an average rating of “Buy” and a consensus price target of $26.90.

In other Voyager Therapeutics news, insider Bernard Ravina sold 3,630 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $16.40, for a total value of $59,532.00. Following the transaction, the insider now directly owns 7,353 shares in the company, valued at approximately $120,589.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 14,610 shares of company stock worth $207,158 over the last 90 days. 8.00% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/17/voyager-therapeutics-vygr-receives-daily-media-sentiment-score-of-0-14.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.